These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 17642236)

  • 1. [Antibody to IL-1 or IL-15].
    Akama H
    Nihon Rinsho; 2007 Jul; 65(7):1227-30. PubMed ID: 17642236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Interleukin-15 in pathogenesis of rheumatoid arthritis].
    Shimada K
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():167-9. PubMed ID: 15799339
    [No Abstract]   [Full Text] [Related]  

  • 3. Pathogenesis of rheumatoid arthritis: targeting cytokines.
    Zwerina J; Redlich K; Schett G; Smolen JS
    Ann N Y Acad Sci; 2005 Jun; 1051():716-29. PubMed ID: 16127012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-33: a promising therapeutic target for rheumatoid arthritis?
    Yuan FL; Li X; Lu WG; Li CW; Xu RS; Dong J
    Expert Opin Ther Targets; 2011 May; 15(5):529-34. PubMed ID: 21446881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on cytokines in rheumatoid arthritis.
    Brennan F; Beech J
    Curr Opin Rheumatol; 2007 May; 19(3):296-301. PubMed ID: 17414959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.
    Nakahara H; Song J; Sugimoto M; Hagihara K; Kishimoto T; Yoshizaki K; Nishimoto N
    Arthritis Rheum; 2003 Jun; 48(6):1521-9. PubMed ID: 12794819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis.
    Dayer JM
    Rheumatology (Oxford); 2003 May; 42 Suppl 2():ii3-10. PubMed ID: 12817089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist.
    Butler DM; Maini RN; Feldmann M; Brennan FM
    Eur Cytokine Netw; 1995; 6(4):225-30. PubMed ID: 8789287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralizing IL-21 and IL-15 inhibits pro-inflammatory cytokine production in rheumatoid arthritis.
    Andersson AK; Feldmann M; Brennan FM
    Scand J Immunol; 2008 Jul; 68(1):103-11. PubMed ID: 18482208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-1beta influences the effect of infliximab on temporomandibular joint pain in rheumatoid arthritis.
    Kopp S; Alstergren P; Ernestam S; Nordahl S; Bratt J
    Scand J Rheumatol; 2006; 35(3):182-8. PubMed ID: 16766364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin 1 (IL-1) receptor antagonist, soluble tumor necrosis factor receptors, IL-1 beta, and IL-8--markers of remission in rheumatoid arthritis during treatment with methotrexate.
    Seitz M; Loetscher P; Dewald B; Towbin H; Rordorf C; Gallati H; Gerber NJ
    J Rheumatol; 1996 Sep; 23(9):1512-6. PubMed ID: 8877917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of interleukin-1 in the pathogenesis of rheumatoid arthritis.
    Kay J; Calabrese L
    Rheumatology (Oxford); 2004 Jun; 43 Suppl 3():iii2-iii9. PubMed ID: 15150426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study.
    Baslund B; Tvede N; Danneskiold-Samsoe B; Larsson P; Panayi G; Petersen J; Petersen LJ; Beurskens FJ; Schuurman J; van de Winkel JG; Parren PW; Gracie JA; Jongbloed S; Liew FY; McInnes IB
    Arthritis Rheum; 2005 Sep; 52(9):2686-92. PubMed ID: 16142748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A distinct multicytokine profile is associated with anti-cyclical citrullinated peptide antibodies in patients with early untreated inflammatory arthritis.
    Hitchon CA; Alex P; Erdile LB; Frank MB; Dozmorov I; Tang Y; Wong K; Centola M; El-Gabalawy HS
    J Rheumatol; 2004 Dec; 31(12):2336-46. PubMed ID: 15570632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis.
    Paleolog EM; Young S; Stark AC; McCloskey RV; Feldmann M; Maini RN
    Arthritis Rheum; 1998 Jul; 41(7):1258-65. PubMed ID: 9663484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synovial expression of IL-15 in rheumatoid arthritis is not influenced by blockade of tumour necrosis factor.
    Ernestam S; af Klint E; Catrina AI; Sundberg E; Engström M; Klareskog L; Ulfgren AK
    Arthritis Res Ther; 2006; 8(1):R18. PubMed ID: 16507118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-6 subfamily cytokines and rheumatoid arthritis: role of antagonists.
    Jazayeri JA; Carroll GJ; Vernallis AB
    Int Immunopharmacol; 2010 Jan; 10(1):1-8. PubMed ID: 19804846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Future trends in the treatment of rheumatoid arthritis: cytokine targets.
    Breedveld FC
    Rheumatology (Oxford); 1999 Nov; 38 Suppl 2():11-3. PubMed ID: 10646483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic potential of IL-15 in rheumatoid arthritis.
    Yang XK; Xu WD; Leng RX; Liang Y; Liu YY; Fang XY; Feng CC; Li R; Cen H; Pan HF; Ye DQ
    Hum Immunol; 2015 Nov; 76(11):812-8. PubMed ID: 26429323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of interleukin-1 in bone resorption in rheumatoid arthritis.
    Strand V; Kavanaugh AF
    Rheumatology (Oxford); 2004 Jun; 43 Suppl 3():iii10-iii16. PubMed ID: 15150427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.